201 related articles for article (PubMed ID: 15831912)
1. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.
Sträter J; Hinz U; Hasel C; Bhanot U; Mechtersheimer G; Lehnert T; Möller P
Gut; 2005 May; 54(5):661-5. PubMed ID: 15831912
[TBL] [Abstract][Full Text] [Related]
2. CD95 ligand expression in dedifferentiated breast cancer.
Müschen M; Moers C; Warskulat U; Niederacher D; Betz B; Even J; Lim A; Josien R; Beckmann MW; Häussinger D
J Pathol; 1999 Nov; 189(3):378-86. PubMed ID: 10547600
[TBL] [Abstract][Full Text] [Related]
3. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
4. Fas-related apoptosis in gastric adenocarcinoma.
Lim SC
Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
[TBL] [Abstract][Full Text] [Related]
5. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
6. Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.
Yao H; Song E; Chen J; Hamar P
Br J Cancer; 2004 Nov; 91(9):1718-25. PubMed ID: 15494722
[TBL] [Abstract][Full Text] [Related]
7. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival.
Neuber K; Eidam B
Onkologie; 2006 Sep; 29(8-9):361-5. PubMed ID: 16974112
[TBL] [Abstract][Full Text] [Related]
8. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis.
Lee WS; Kang M; Baek JH; Lee JI; Ha SY
Ann Surg Oncol; 2013 Feb; 20(2):697-702. PubMed ID: 23224827
[TBL] [Abstract][Full Text] [Related]
10. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer.
Poincloux L; Durando X; Seitz JF; Thivat E; Bardou VJ; Giovannini MH; Parriaux D; Barriere N; Giovannini M; Delpero JR; Monges G
Surg Oncol; 2009 Dec; 18(4):357-65. PubMed ID: 19027288
[TBL] [Abstract][Full Text] [Related]
11. FAS and FAS-L expression by tumor cells and lymphocytes in breast carcinomas and their lymph node metastases.
Ioachim HL; Decuseara R; Giancotti F; Dorsett BH
Pathol Res Pract; 2005; 200(11-12):743-51. PubMed ID: 15792116
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis by IFNgamma in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit.
Bernassola F; Scheuerpflug C; Herr I; Krammer PH; Debatin KM; Melino G
Cell Death Differ; 1999 Jul; 6(7):652-60. PubMed ID: 10453076
[TBL] [Abstract][Full Text] [Related]
13. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma.
Bellone G; Smirne C; Carbone A; Mareschi K; Dughera L; Farina EC; Alabiso O; Valente G; Emanuelli G; Rodeck U
Clin Cancer Res; 2000 Jun; 6(6):2448-55. PubMed ID: 10873098
[TBL] [Abstract][Full Text] [Related]
14. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications.
Strand S; Galle PR
Mol Med Today; 1998 Feb; 4(2):63-8. PubMed ID: 9547792
[TBL] [Abstract][Full Text] [Related]
15. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo.
Houston A; Waldron-Lynch FD; Bennett MW; Roche D; O'Sullivan GC; Shanahan F; O'Connell J
Int J Cancer; 2003 Nov; 107(2):209-14. PubMed ID: 12949796
[TBL] [Abstract][Full Text] [Related]
16. Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence.
Belt EJ; Stockmann HB; Delis-van Diemen PM; Bril H; Tijssen M; van Essen HF; Heymans MW; Beliën JA; Carvalho B; Cillessen SA; Meijer GA
J Surg Oncol; 2014 Mar; 109(3):255-65. PubMed ID: 24249458
[TBL] [Abstract][Full Text] [Related]
17. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis.
von Reyher U; Sträter J; Kittstein W; Gschwendt M; Krammer PH; Möller P
Cancer Res; 1998 Feb; 58(3):526-34. PubMed ID: 9458101
[TBL] [Abstract][Full Text] [Related]
18. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
Michael-Robinson JM; Pandeya N; Cummings MC; Walsh MD; Young JP; Leggett BA; Purdie DM; Jass JR; Radford-Smith GL
J Pathol; 2003 Sep; 201(1):46-54. PubMed ID: 12950016
[TBL] [Abstract][Full Text] [Related]
19. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.
Tolomeo M; Dusonchet L; Meli M; Grimaudo S; D'Alessandro N; Papoff G; Ruberti G; Rausa L
Cell Death Differ; 1998 Sep; 5(9):735-42. PubMed ID: 10200532
[TBL] [Abstract][Full Text] [Related]
20. Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines.
van Geelen CM; de Vries EG; Le TK; van Weeghel RP; de Jong S
Br J Cancer; 2003 Jul; 89(2):363-73. PubMed ID: 12865931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
